stockrow
Friday 6 November 2026
Export RPID’s income statement to Excel — free account
Rapid Micro Biosystems, Inc.
RPID Healthcare Medical Devices
Rapid Micro Biosystems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.6 million, up 19.7% from fiscal 2024.
- Revenue
- +10.9%
- EPS
- 0.00%
- Free cash flow
- −24.0%
Quarter to June 2026, against a year earlier
0.64
0.02
+3.23%
Follow RPID
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.38 | 3.00 | 3.86 | 4.92 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.58) | (6.85) | (39.92) | (16.59) | |
P/B ratio |
4.71 | 5.06 | 3.90 | 3.39 | |
Price to Tangible BV |
4.71 | 5.06 | 3.90 | 3.39 | |
EV/Sales |
2.36 | 2.89 | 3.28 | 4.18 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.07) | (2.68) | (3.55) | (3.39) | |
EV/FCF |
(2.06) | (2.61) | (3.45) | (3.31) | |
Quick Ratio |
1.39 | 1.53 | 2.24 | 2.82 | |
Current Ratio |
2.55 | 2.57 | 3.31 | 4.23 | |
Net Debt/EBITDA |
0.05 | 0.30 | 1.70 | 2.12 | |
Debt/Assets |
32.74% | 30.55% | 25.25% | 22.31% | |
Debt/Equity |
1.08 | 0.93 | 0.57 | 0.42 | |
Asset Turnover |
0.52 | 0.47 | 0.39 | 0.32 | |
Operating CF/Net income |
0.98 | 1.05 | 0.26 | 0.79 | |
Capex/Depreciation |
0.29 | (0.50) | (0.12) | (0.09) | |
Interest Coverage |
(19.07) | (21.68) | (18.14) | (28.94) | |
Research and Development Expense of Revenue |
41.37% | 41.98% | 28.54% | 45.02% | |
Selling, General and Administrative Expense of Revenue |
126.67% | 135.77% | 76.79% | 108.94% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
16.40% | 15.28% | 5.56% | 14.62% | |
Graham Net Nets |
0.07 | 0.07 | 0.15 | 0.20 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(64.74%) | (49.34%) | (36.90%) | (30.24%) | |
Free Cash Flow Yield |
(48.29%) | (36.83%) | (24.63%) | (25.69%) | |
Revenue per Share |
0.17 | 0.18 | 0.25 | 0.17 | |
Operating CF per Share |
(0.26) | (0.33) | (0.07) | (0.20) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.26) | (0.34) | (0.07) | (0.20) | |
Cash per Share |
0.41 | 0.51 | 0.86 | 0.92 | |
Shareholders Equity per Share |
0.37 | 0.45 | 0.74 | 0.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.37 | 0.45 | 0.74 | 0.99 | |
Free Cash Flow |
(12.48) | (15.45) | (3.34) | (9.12) | |
Working Capital |
28.11 | 30.11 | 42.68 | 53.40 | |
Capital Expenditures |
0.22 | (0.39) | (0.09) | (0.07) | |
Net Current Asset Value |
5.56 | 7.26 | 19.52 | 29.88 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.03) | 0.05 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.78 | 5.44 | 5.33 | 4.59 | |
Average Payables |
4.26 | 3.65 | 3.34 | 2.96 | |
Average Inventory |
19.74 | 19.08 | 18.90 | 21.16 | |
Average Assets |
67.02 | 73.90 | 86.51 | 95.13 | |
Average Common Equity |
36.15 | 42.94 | 54.28 | 64.35 |
Columns are period end dates · fundamentals updated 26 Oct 2026